Global Radiofrequency Ablation Market 2017-2021
About Radiofrequency Ablation
Radiofrequency ablation devices are used to treat medical conditions such as cancer tumors with the help of imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound by using minimally invasive (MI) techniques. This involves the use of high-frequency electromagnetic waves to generate heat energy (alternating current). Radiofrequency ablation is used by surgeons to destroy cancerous cells, and remove or trim obstructive tissues and dead nerves. The process is carried out by inserting a special needle through the skin onto the tumor. The procedure targets specific tissue/nerve with radiofrequency electrical energy, heating the tumor through an active exposed electrode tip.
Technavio’s analysts forecast the global radiofrequency ablation market to grow at a CAGR of 8.78% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global radiofrequency ablation market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of equipment and accessories used in radiofrequency ablation.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Radiofrequency Ablation Market 2017-2021
Technavio recognizes the following companies as the key players in the global radiofrequency ablation market: AngioDynamics, Boston Scientific, Medtronic, St. Jude Medical, and Stryker.
Other Prominent Vendors in the market are: Accuray, Advanced Cardiac Therapeutics, APT Medical, Arthrex, AtriCure, Biosense Webster, BIOTRONIK, Bovie Medical, CardioFocus, CONMED, DVx, Hansen Medical, Halyard Health, Imricor Medical Systems, Japan Lifeline, Merit Medical Systems, MicroPort Scientific, Osypka Medical, PLC Medical Systems, RF Medical, Smith & Nephew, Spacelabs Healthcare, Spectranetics, Theraclion, and Total Vein Systems.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is new product launches coupled with R&D activities. Vendors are increasingly focusing on the development and launch of new radiofrequency ablation devices. Product launches and R&D activities will help vendors survive in the market and enhance their growth. Vendors such as Medtronic, Boston Scientific, AngioDynamics, and Merit Medical Systems are actively involved in the development of innovative devices for improving the efficacy of radiofrequency ablation procedures.”
According to the report, one of the major drivers for this market is increasing incidence of chronic disorders and growing older population. A sedentary lifestyle can negatively affect the homeostasis of the body. The dietary habits of people worldwide are changing, which make them susceptible to many disorders such as cardiovascular diseases, respiratory diseases, obesity, cancer, urology disorders, joint pain, Alzheimer's disease, and other chronic illnesses. According to the CDC data, the number of people with chronic disorders has been increasing steadily over the past two decades. So, the emphasis and focus on treatments for these diseases such as radiofrequency ablation have increased. Radiofrequency ablation devices are increasingly used to treat chest pain, joint pain, gynecological conditions, and liver and kidney problems.
Further, the report states that one of the major factors hindering the growth of this market is risks and complications associated with radiofrequency ablation. Although radiofrequency ablation is a proven MI procedure with high efficacy, certain risks and complications are associated with the procedure, which will hinder the growth prospects and will restrict their adoption among end-users. The use of energy-based ablation devices involves risks and complications not only to patients but also to physicians and operators. These devices emit hazardous radiation that can have serious, even fatal, side-effects. High-power energy devices can damage the sensitive part of the eye and the skin.
AngioDynamics, Boston Scientific, Medtronic, St. Jude Medical, Stryker, Accuray, Advanced Cardiac Therapeutics, APT Medical, Arthrex, AtriCure, Biosense Webster, BIOTRONIK, Bovie Medical, CardioFocus, CONMED, DVx, Hansen Medical, Halyard Health, Imricor Medical Systems, Japan Lifeline, Merit Medical Systems, MicroPort Scientific, Osypka Medical, PLC Medical Systems, RF Medical, Smith & Nephew, Spacelabs Healthcare, Spectranetics, Theraclion, and Total Vein Systems.